Ataraxis AI develops AI-native prognostic and predictive digital diagnostic assays that integrate multi-modal patient data to assess cancer aggressiveness and predict treatment outcomes. Their technology enables physicians to make informed treatment decisions for breast cancer patients, improving accuracy in identifying low- and high-risk cases compared to standard genomic assays.
Funding
$24.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for assessing cancer aggressiveness and predicting treatment outcomes often rely on single data modalities and can have long turnaround times. This can lead to inaccurate risk stratification and suboptimal treatment decisions for cancer patients.
Solution
Ataraxis AI develops AI-native digital diagnostic assays that integrate multi-modal patient data, including clinical, morphological, and molecular information, to improve cancer prognosis and treatment selection. Their technology leverages AI foundation models, such as Kestrel, trained on hundreds of millions of pan-cancer pathology slide images to identify novel features correlated with patient outcomes and treatment response. Ataraxis Breast, their first product, is a prognostic and predictive test for breast cancer that has demonstrated improved accuracy in identifying low- and high-risk patients compared to standard genomic assays. The AI-driven approach enables same-day turnaround time and spares valuable tissue, providing physicians with timely and comprehensive insights for personalized treatment planning.
Target Audience
The primary target audience includes physicians, oncologists, and healthcare providers involved in cancer diagnosis, prognosis, and treatment selection, particularly for breast cancer patients.
Features
- AI-native assays integrating clinical, morphological, and molecular data modalities
- Kestrel pan-cancer foundation model trained on extensive pathology slide image data
- Ataraxis Breast for improved breast cancer prognosis and treatment prediction
- Identification of novel clinical, morphological, and molecular features correlated with patient outcomes
- Same-day turnaround time for rapid clinical decision-making
- Reduced tissue consumption compared to traditional molecular genomic tests
- Clinically validated using data from thousands of patients across multiple institutions